What is the use of Itolizumab injection?
Mia Ramsey Efficacy and Safety of Itolizumab in COVID-19 Complications
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Acute Respiratory Distress Syndrome Cytokine Release Syndrome Covid19 | Drug: Itolizumab IV infusion Drug: Best supportive care (BSC) | Phase 2 |
Does Itolizumab cure psoriasis?
A number of biologics is being used for the treatment of psoriasis. Itolizumab is one such agent which has been approved in India. It is an anti-CD6 monoclonal antibody that acts by binding to scavenger receptor cysteine-rich (SRCR) distal domain 1 of CD6.
What are Zumab drugs?
Human monoclonal antibodies (suffix -umab) are produced using transgenic mice or phage display libraries by transferring human immunoglobulin genes into the murine genome and vaccinating the transgenic mouse against the desired antigen, leading to the production of appropriate monoclonal antibodies.
How can I get Itolizumab injection?
Explore similar products View all products in Itolizumab Injection
- Itolizumab Alzumab Injection, Biocon, 25mg. ₹ 23,000 / Piece.
- ₹ 34,999 / Box. By Jeewan Pharmaceuticals Chandigarh.
- ₹ 30,000 / Unit. By Garg Pharmaceauticals.
- ₹ 31,800 / Vial. By Vishal Medical Store Lucknow, Uttar Pradesh, Lucknow, Uttar Pradesh.
How is tocilizumab eliminated?
After IV dosing, tocilizumab undergoes biphasic elimination from the circulation. In patients with RA, the central volume of distribution was 3.5 L, and the peripheral volume of distribution was 2.9 L, resulting in a volume distribution at steady state of 6.4 L.
Can psoriasis patients take Covishield?
12. Can patients with Rheumatoid Arthritis, Psoriasis, SLE, ankylosing spondylitis, sickle cell disease, any cancer or any other disease take the vaccine? History of any disease is not a contraindication for receiving the vaccine.
What is tocilizumab injection?
Tocilizumab injection is in a class of medications called interleukin-6 (IL-6) receptor inhibitors. It works by blocking the activity of interleukin-6, a substance in the body that causes inflammation.
What is Alzumab injection?
Alzumab Injection is a new medicine developed and approved in India for the treatment of psoriasis. It may also be used for the treatment of certain other autoimmune diseases such as rheumatoid arthritis, multiple sclerosis, etc.
What is the mechanism of action of tocilizumab?
Summary: Tocilizumab is a novel monoclonal antibody that competitively inhibits the binding of interleukin-6 (IL-6) to its receptor (IL-6R). Inhibiting the entire receptor complex prevents IL-6 signal transduction to inflammatory mediators that summon B and T cells.
What is the mechanism of action of adalimumab?
Adalimumab is a fully human IgG1 monoclonal antibody that specifically binds to tumor necrosis factor (TNF)-alpha, and is administered by subcutaneous injection. The mechanism of action is based on both the neutralization of TNF-alpha bioactivity and the induction of apoptosis of TNF-expressing mononuclear cells.
What is Itolizumab (alsumab)?
Itolizumab (INN, trade name Alzumab) is a ‘first in class’ humanized IgG1 monoclonal antibody developed by Biocon. It selectively targets CD6, a pan T cell marker involved in co-stimulation, adhesion and maturation of T cells.
Is monoclonal anti-cd6 antibody Itolizumab useful in psoriasis?
This article deals with a new humanized monoclonal anti-CD6 antibody, Itolizumab, which has been found to be useful in the treatment of psoriasis because it has a better side effects profile. Role of immune cells and co-stimulatory signals in pathogenesis of psoriasis
Is Alzumab available in India?
Itolizumab was launched in India in 2013 under the brand name ALZUMAb™. Itolizumab is Biocon’s second ‘lab to market’ novel biologic after Nimotuzumab and offers a ‘best-in-class’ biologic drug for acute psoriasis.
Where is equillium’s Itolizumab being used?
Equillium has three clinical studies underway across the globe for Itolizumab in acute graft-versus-host disease (aGVHD), severe Asthma and Lupus Nephritis. The scope of our licensing agreement with Equillium for Itolizumab, which initially covered U.S. and Canada, was extended to include Australia and New Zealand in FY20.
